Over the past year, and for the first time ever, the US Food and Drug Administration approved 2 drugs specifically for the treatment of lupus nephritis (LN). As the lupus community works toward understanding how to best use these new therapies, it is also an ideal time to begin to rethink the overall management strategy of LN. In addition to new drugs, this must include how to use kidney biopsies for management and not just diagnosis, how molecular technologies can be applied to interrogate biopsies and how such data can impact management, and how to incorporate LN biomarkers into management paradigms. Herein, we will review new developments in these areas of LN and put them into perspective for disease management now and in the future. Copyright © 2021 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Citation
Juan M Mejia-Vilet, Ana Malvar, Arnon Arazi, Brad H Rovin. The lupus nephritis management renaissance. Kidney international. 2022 Feb;101(2):242-255
Mesh Tags
Substances
PMID: 34619230
View Full Text
